ResMed Inc. (USD) ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

ResMed Inc. (USD) Active

9001 Spectrum Center Boulevard, San Diego, CA, US, 92123

Stock Price USD

Price Change

Last Dividend USD

Latest Rating

RMD's stock peer is A (Agilent Technologies, Inc.)

RMD's stock peer is BDX (Becton, Dickinson and Company)

RMD's stock peer is CAH (Cardinal Health, Inc.)

RMD's stock peer is GEHC (GE HealthCare Technologies Inc.)

RMD's stock peer is INSM (Insmed Incorporated)

RMD's stock peer is IQV (IQVIA Holdings Inc.)

RMD's stock peer is MTD (Mettler-Toledo International Inc.)

Healthcare Medical - Devices

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

100%

Dcf Rating

100%

Return On Equity

100%

Return On Assets

60%

Debt To Equity

40%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-05-14	2026-06-18	0.60	1.19 %	Quarterly
2026-02-12	2026-03-19	0.60	0.95 %	Quarterly
2025-11-13	2025-12-18	0.60	0.90 %	Quarterly
2025-08-14	2025-09-18	0.60	0.77 %	Quarterly
2025-05-08	2025-06-12	0.53	0.87 %	Quarterly
2025-02-13	2025-03-20	0.53	0.86 %	Quarterly
2024-11-07	2024-12-12	0.53	0.81 %	Quarterly
2024-08-15	2024-09-19	0.53	0.87 %	Quarterly
2024-05-09	2024-06-13	0.48	0.90 %	Quarterly
2024-02-08	2024-03-14	0.48	1.01 %	Quarterly
2023-11-09	2023-12-14	0.48	1.24 %	Quarterly
2023-08-17	2023-09-21	0.48	1.04 %	Quarterly
2023-05-11	2023-06-15	0.44	0.75 %	Quarterly
2023-02-09	2023-03-16	0.44	0.79 %	Quarterly
2022-11-10	2022-12-15	0.44	0.81 %	Quarterly
2022-08-18	2022-09-22	0.44	0.72 %	Quarterly
2022-05-12	2022-06-16	0.42	0.88 %	Quarterly
2022-02-10	2022-03-17	0.42	0.67 %	Quarterly
2021-11-11	2021-12-16	0.42	0.62 %	Quarterly
2021-08-19	2021-09-23	0.42	0.57 %	Quarterly
2021-05-13	2021-06-17	0.39	0.81 %	Quarterly
2021-02-11	2021-03-18	0.39	0.78 %	Quarterly
2020-11-12	2020-12-17	0.39	0.74 %	Quarterly
2020-08-20	2020-09-24	0.39	0.85 %	Quarterly
2020-05-14	2020-06-18	0.39	0.95 %	Quarterly
2020-02-13	2020-03-19	0.39	0.89 %	Quarterly
2019-11-07	2019-12-12	0.39	1.06 %	Quarterly
2019-08-15	2019-09-19	0.39	1.14 %	Quarterly
2019-05-09	2019-06-13	0.37	1.33 %	Quarterly
2019-02-07	2019-03-14	0.37	1.53 %	Quarterly
2018-11-08	2018-12-13	0.37	1.34 %	Quarterly
2018-08-16	2018-09-20	0.37	1.33 %	Quarterly
2018-05-10	2018-06-14	0.35	1.43 %	Quarterly
2018-02-08	2018-03-15	0.35	1.49 %	Quarterly
2017-11-09	2017-12-14	0.35	1.65 %	Quarterly
2017-08-17	2017-09-21	0.35	1.85 %	Quarterly
2017-05-11	2017-06-15	0.33	1.96 %	Quarterly
2017-02-09	2017-03-16	0.33	1.87 %	Quarterly
2016-11-10	2016-12-15	0.33	2.19 %	Quarterly
2016-08-18	2016-09-22	0.33	1.78 %	Quarterly
2016-05-19	2016-06-16	0.30	2.10 %	Quarterly
2016-02-11	2016-03-17	0.30	2.06 %	Quarterly
2015-11-19	2015-12-17	0.30	2.01 %	Quarterly
2015-08-20	2015-09-17	0.30	2.08 %	Quarterly
2015-05-21	2015-06-18	0.28	1.97 %	Quarterly
2015-02-12	2015-03-19	0.28	1.71 %	Quarterly
2014-11-20	2014-12-18	0.28	2.03 %	Quarterly
2014-08-21	2014-09-18	0.28	2.00 %	Quarterly
2014-05-20	2014-06-17	0.25	1.98 %	Quarterly
2014-02-19	2014-03-19	0.25	2.01 %	Quarterly
2013-11-19	2013-12-18	0.25	1.65 %	Quarterly
2013-08-20	2013-09-17	0.25	1.53 %	Quarterly
2013-05-21	2013-06-18	0.17	1.36 %	Quarterly
2013-02-19	2013-03-19	0.17	1.18 %	Quarterly
2012-11-20	2012-12-18	0.17	0.87 %	Quarterly
2012-09-07	2012-09-28	0.17	0.44 %	Quarterly

Recent News

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.

2026-06-03 07:40:00

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).

2026-06-01 16:05:00

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time).

2026-05-19 16:05:00

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world's leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health. Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care.

2026-05-19 09:00:00

Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.

2026-04-30 16:10:00

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%; non-GAAP income from operations up 18% GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86 Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.

2026-04-30 16:05:00

Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

2026-04-01 16:05:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions